Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin T Ernst

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Angewandte Chemie (International Ed. in English)|February 6, 2003
Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complexJustin T Ernst, Jorge Becerril, Hyung Soon Park, et al.
AIDS Research and Human Retroviruses|October 25, 2002
XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41Qian Zhao, Justin T Ernst, Andrew D Hamilton, et al.
Molecular Diversity|June 24, 2004
Protein recognition using synthetic surface-targeted agentsRishi Jain, Justin T Ernst, Olaf Kutzki, et al.
Angewandte Chemie (International Ed. in English)|December 20, 2002
Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusionJustin T Ernst, Olaf Kutzki, Asim K Debnath, et al.
Journal of the American Chemical Society|October 3, 2002
Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicryOlaf Kutzki, Hyung Soon Park, Justin T Ernst, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2013
Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseasesJustin T Ernst, Michael Liu, Harmon Zuccola, et al.
Journal of the American Chemical Society|July 21, 2005
Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xLHang Yin, Gui-In Lee, Kristine A Sedey, et al.
Organic Letters|August 19, 2020
Strategic Diastereoselective C1 Functionalization in the Aza-Rocaglamide Scaffold toward Natural Product-Inspired eIF4A InhibitorsChristian Nilewski, Theodore D Michels, Alan X Xiang, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2021
1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK propertiesChristian Nilewski, Theodore D Michels, Garrick K Packard, et al.
Journal of Medicinal Chemistry|March 29, 2014
Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's diseaseJustin T Ernst, Timothy Neubert, Michael Liu, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Angewandte Chemie (International Ed. in English)|February 6, 2003
Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complexJustin T Ernst, Jorge Becerril, Hyung Soon Park, et al.
AIDS Research and Human Retroviruses|October 25, 2002
XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41Qian Zhao, Justin T Ernst, Andrew D Hamilton, et al.
Molecular Diversity|June 24, 2004
Protein recognition using synthetic surface-targeted agentsRishi Jain, Justin T Ernst, Olaf Kutzki, et al.
Angewandte Chemie (International Ed. in English)|December 20, 2002
Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusionJustin T Ernst, Olaf Kutzki, Asim K Debnath, et al.
Journal of the American Chemical Society|October 3, 2002
Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicryOlaf Kutzki, Hyung Soon Park, Justin T Ernst, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2013
Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseasesJustin T Ernst, Michael Liu, Harmon Zuccola, et al.
Journal of the American Chemical Society|July 21, 2005
Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xLHang Yin, Gui-In Lee, Kristine A Sedey, et al.
Organic Letters|August 19, 2020
Strategic Diastereoselective C1 Functionalization in the Aza-Rocaglamide Scaffold toward Natural Product-Inspired eIF4A InhibitorsChristian Nilewski, Theodore D Michels, Alan X Xiang, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2021
1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK propertiesChristian Nilewski, Theodore D Michels, Garrick K Packard, et al.
Journal of Medicinal Chemistry|March 29, 2014
Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's diseaseJustin T Ernst, Timothy Neubert, Michael Liu, et al.
Pageof 2